OPTIMOX3_3A: OPTIMOX3, figure 3A

OPTIMOX3_3AR Documentation

OPTIMOX3, figure 3A

Description

Kaplan-Meier digitized data from OPTIMOX3, figure 3A (PMID 26474518). A reported sample size of 700 for a primary endpoint of PFS in colorectal cancer.

Usage

OPTIMOX3_3A

Format

A data frame of 452 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (bev, bev_erlotinib)

Source

Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1493–505.

Examples

summary(OPTIMOX3_3A)

kmplot(OPTIMOX3_3A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.